These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1901320)

  • 1. Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial.
    Vaughan Williams EM
    J Clin Pharmacol; 1991 Feb; 31(2):123-35. PubMed ID: 1901320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications.
    Pratt CM; Moye LA
    Am J Cardiol; 1990 Jan; 65(4):20B-29B. PubMed ID: 2105049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
    Cardiac Arrhythmia Suppression Trial (CAST) Investigators
    N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE
    Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flecainide and encainide.
    Furlanello F; Vergara G; Bettini R; Mosna G; Gramegna L; Disertori M
    Eur Heart J; 1987 Mar; 8 Suppl A():33-40. PubMed ID: 3107989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination.
    Biffi M; Boriani G; Bronzetti G; Capucci A; Branzi A; Magnani B
    Heart; 1999 Aug; 82(2):176-82. PubMed ID: 10409531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of the antiarrhythmic action of moricizine.
    Vaughan Williams EM
    J Clin Pharmacol; 1991 Mar; 31(3):216-21. PubMed ID: 2019662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardiac arrhythmia suppression trial: implications for antiarrhythmic drug development.
    Pratt CM; Moye L
    J Clin Pharmacol; 1990 Nov; 30(11):967-74. PubMed ID: 2122983
    [No Abstract]   [Full Text] [Related]  

  • 11. Classifying antiarrhythmic actions: by facts or speculation.
    Vaughan Williams EM
    J Clin Pharmacol; 1992 Nov; 32(11):964-77. PubMed ID: 1474169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease.
    Sarubbi B; Ducceschi V; Briglia N; Mayer MS; Santangelo L; Iacono A
    Int J Cardiol; 1998 Sep; 66(2):157-64. PubMed ID: 9829329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sotalol, propafenone, and flecainide: compared multiparametric analysis of ventricular repolarization in subjects without organic cardiopathy].
    Sarubbi B; Ducceschi V; Briglia N; Esposito R; Mayer MS; Scialdone A; Santangelo L; Iacono A
    Cardiologia; 1996 Jul; 41(7):645-51. PubMed ID: 8983831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial.
    Anderson JL
    J Clin Pharmacol; 1990 Nov; 30(11):981-9. PubMed ID: 2122984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Class-I antiarrhythmic drugs].
    Kuga K; Sugishita Y
    Nihon Rinsho; 1996 Aug; 54(8):2110-6. PubMed ID: 8810785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
    Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL
    J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
    Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL
    N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The events surrounding the removal of encainide and flecainide from the Cardiac Arrhythmia Suppression Trial (CAST) and why CAST is continuing with moricizine.
    Bigger JT
    J Am Coll Cardiol; 1990 Jan; 15(1):243-5. PubMed ID: 2104884
    [No Abstract]   [Full Text] [Related]  

  • 20. Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock.
    Follmer CH; Cullinan CA; Colatsky TJ
    Cardiovasc Res; 1992 Nov; 26(11):1121-30. PubMed ID: 1291091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.